RishiKakarMD

Psychiatry • Tamarac, FL

Neuropsychiatry, Psychopharmacology, Psychosomatic Medicine, Integrative Psychiatry

Chief Scientific Officer/Medical Director

Join to view full profile

Dr. Kakar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kakar's full profile

Already have an account?

Office
7481 W Oakland Park Blvd
Ste 100
Tamarac, FL 33319
Phone+1 954-771-7743

Fax+1 954-771-7488

Summary

I am board certified psychiatrist with additional training from National Institute of Mental Health. I am currently a Medical Director for a large research institute a and primary investigator for numerous phase I- IV clinical trials. I am actively conducting studies in depression,anxiety, bipolar, schizophrenia, pain, dementia and
substance use. I also have a clinical practice where I see adults and adolescents with various psychiatric disorders. I am especially interested in integrating mind body approaches, nutritional methods, ortho molecular techniques along with traditional pharmacological regimen to treat my patients.

Education & Training

Clinical Center at the National Institutes of HealthFellowship, Psychosomatic Medicine, 2010 - 2011
MedStar Health/Georgetown University HospitalResidency, Psychiatry, 2008 - 2010
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Neurology, 2007 - 2007
Saint Peter's University Hospital/Rutgers Robert Wood Johnson Medical SchoolInternship, Internal Medicine, 2006 - 2007
Albany Medical CollegeClass of 2006

Certifications & Licensure

CA State Medical License 2017 - Present
FL State Medical License 2011 - 2025
MD State Medical License 2010 - 2012
DC State Medical License 2008 - 2010
PA State Medical License 2007 - 2008
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

FL Top Doctor Award 2018
Elected member Alpha Omega Alpha, 2006

Clinical Trials

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia Start of enrollment: 2008 Sep 01
Completed
Phase 3
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD) Start of enrollment: 2012 Nov 01
Completed
Phase 2
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Start of enrollment: 2013 Oct 01
Completed
Phase 2
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia Start of enrollment: 2014 Mar 26
Completed
Phase 2
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients Start of enrollment: 2014 Apr 01
Completed
Phase 3
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia Start of enrollment: 2014 Jun 01
Completed
Phase 3
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine Start of enrollment: 2015 Jan 28
Completed
Phase 3
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) Start of enrollment: 2015 Sep 01
Completed
Not Applicable
Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder Start of enrollment: 2015 Jul 27
Completed
Phase 3
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2) Start of enrollment: 2016 Feb 16
Completed
Phase 3
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence Start of enrollment: 2015 Dec 01
Completed
Phase 3
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant Start of enrollment: 2015 Oct 01
Completed
Phase 2
Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety Start of enrollment: 2016 May 01
Completed
Not Applicable
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD Start of enrollment: 2018 May 11
Completed
Phase 2
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder Start of enrollment: 2017 Jun 12
Completed
Phase 2
Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD) Start of enrollment: 2017 Dec 04
Completed
Not Applicable
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD Start of enrollment: 2018 Mar 13
Completed
Phase 3
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder Start of enrollment: 2018 Jul 13
Completed
Phase 3
A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder Start of enrollment: 2019 Jan 16
Completed
Phase 3
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder Start of enrollment: 2019 Feb 14
Completed
Phase 3
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression Start of enrollment: 2018 Jun 06
Completed
Phase 1
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. Start of enrollment: 2019 Nov 15
Completed
Phase 3
Single Ascending Dose Study of ALA-1000 Start of enrollment: 2019 Sep 16
Completed
Phase 1
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD Start of enrollment: 2023 Feb 14
Recruiting
Phase 3
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Start of enrollment: 2021 Sep 08
Completed
Phase 1
ANC-501 in the Treatment of Adults With Major Depressive Disorder Start of enrollment: 2022 Sep 19
Active, not recruiting
Phase 2
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes Start of enrollment: 2021 Mar 23
Active, not recruiting
Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) Start of enrollment: 2022 May 06
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

45 citations
Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.
Sheldon H Preskorn, Scott Zeller, Leslie Citrome, Jeffrey Finman, Joseph F Goldberg
JAMA. 2022-02-22
21 citations
A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.
Anke Post, Trevor S Smart, Judith Krikke-Workel, Gerard R Dawson, Catherine J Harmer
Neuropsychopharmacology. 2016-06-01
153 citations
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Barbara R. Haight, Susan M Learned, Céline M. Laffont, Paul J. Fudala, Y Zhao
Lancet. 2019-02-23

Journal Articles

FIRST Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-bl...
Inder Kaul, MD Sharon Sawchak, RN Prof Christoph U Correll, MD Rishi Kakar, MD Prof Alan Breier, MD Haiyuan Zhu, PhD Andrew C Miller, PhD Steven M Paul, MD Stephen K ..., The Lancet, 12/14/2023

Abstracts/Posters

Translational Research with Dexmedetomidine (DM) for the Treatment of Agitation from Healthy Volunteers to Two Patient groups: Those with Schizophrenia or with Probabl...
Sheldon Preskorn , Rishi Kakar , Hrishikesh Kumar , Sameer Sharma† , Vince O’Neill† , Robert Risinger† , Frank Yocca†, American Society of Clinical Psychopharmacology, Scottsdale, AZ, 5/2019
Clinical training in Neurosciences: NIMH perspective
Kakar, R. Akil, M, Pao, M, Journal of Biological Psychiatry, 4/2011

Press Mentions

FDA Approves Cobenfy for Adults with SchizophreniaNovember 15th, 2024
The First New Schizophrenia Drug in DecadesOctober 1st, 2024
What to Know About Cobenfy, First New FDA-Approved Treatment for Schizophrenia in DecadesSeptember 30th, 2024
Join now to see all

Research History

Research Fellow, NIMHPsychosomatic fellow/Georgetown Resident2010 - 2011

Professional Memberships

American Society of Clinical Psychopharmacology
Member
American Psychiatric Association - APA
Member
Schizophrenia Interest Research Society
Member

Industry Relationships

Speaker/Consultant, Otsuka LUNDBECK2017 - 2020
Coordinating Investigator, Eli LillyCoordinating investigator, medical review 15-MJ- NOAC clinical study2014 - 2014
Consultant, Neurocrine Biosciences2013 - 2014